| [1] |
Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2025 update[J]. Int J Gynaecol Obstet, 2025, 171(Suppl 1): 78-86. DOI: 10.1002/ijgo.70275.
|
| [2] |
Braga A, Mora P, de Melo AC, et al. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide[J]. World J Clin Oncol, 2019, 10(2): 28-37. DOI: 10.5306/wjco.v10.i2.28.
|
| [3] |
|
| [4] |
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice[J]. Nat Rev Immunol, 2020, 20(11): 651-668. DOI: 10.1038/s41577-020-0306-5.
|
| [5] |
McNally L, Wu S, Hodges K, et al. Molecular profiling of gestational trophoblastic neoplasia: identifying therapeutic targets[J]. Gynecol Oncol, 2024, 184(1): 111-116. DOI: 10.1016/j.ygyno.2024.01.033.
|
| [6] |
Htanaka K, Higashi M, Fujibayashi M, et al. A case of complete hydatidiform mole in a perimenopausal woman with diagnostic usefulness of p57kip2 immunohistochemistry and HER2 fluorescent in situ hybridization[J]. Pathol Res Pract, 2012, 208(1): 118-120. DOI: 10.1016/j.prp.2011.11.005.
|
| [7] |
Lala PK, Nandi P, Hadi A, et al. A crossroad between placental and tumor biology: what have we learnt[J]. Placenta, 2021, 116(1): 12-30. DOI: 10.1016/j.placenta.2021.03.003.
|
| [8] |
Veras E, Kurman RJ, Wang TL, et al. PD-L1 expression in human placentas and gestational trophoblastic diseases[J]. Int J Gynecol Pathol, 2017, 36(2): 146-153. DOI: 10.1097/PGP.0000000000000305.
|
| [9] |
Choi MC, Oh J, Lee C. Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia[J]. Eur J Cancer, 2019, 121(1): 94-97. DOI: 10.1016/j.ejca.2019.08.024.
|
| [10] |
Zeng J, Zhang J, Wang J, et al. Immunotherapy in gestational trophoblastic neoplasia: advances and future directions[J]. Front Immunol, 2025, 16: 1544585. DOI: 10.3389/fimmu.2025.1544585.
|
| [11] |
|
| [12] |
Zong L, Zhang M, Wang W, et al. PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia[J/OL]. Histopathology, 2019, 75(3): 421-430. DOI: 10.1111/his.13882.
|
| [13] |
You B, Bolze PA, Lotz JP, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN phase Ⅱ trial[J/OL]. J Clin Oncol, 2020, 38(27): 3129-3137. DOI: 10.1200/jco.20.008038.
|
| [14] |
You B, Lotz JP, Descargues P, et al. 7110 Avelumab ＋ methotrexate to eradicate low-risk gestational trophoblastic tumors in first-line setting: TROPHAMET phase Ⅰ/Ⅱ trial[J]. Ann Oncol, 2024, 35(Supp 2): S545. DOI: 10.1016/j.annonc.2024.08.772.
|
| [15] |
Wang W, Yang J, Xiang Y. Advancing immunotherapy in gestational trophoblastic neoplasia: current progress and future directions[J]. Gynecol Obstet Clin Med, 2025, 5: e000194. DOI： 10.1136/gocm-2024-000194.
|
| [16] |
You B, Bolze P, Lotz J, et al. 273 Avelumab in patients with gestational trophoblastic tumors resistant to polychemotherapy: efficacy outcomes of cohort B of TROPHIMMUN phase Ⅱ trial[J]. Trophoblastic Diseases, 2021, 31(Supp 1): A344.2-A344. DOI: 10.1136/ijgc-2021-esgo.608.
|
| [17] |
Cheng H, Yang J, Zhao J, et al. 177 Camrelizumab combined with apatinib for refractory gestational trophoblastic neoplasia: a phase 2, single-arm, prospective study[J]. Int J Gynecol Cancer, 2020, 30(Suppl 3): A76. DOI: 10.1136/IJGC-2020-IGCS.154.
|
| [18] |
Wang X, Cang W, Liu X, et al. Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective study[J]. EClinicalMed, 2023, 59: 101974. DOI: 10.1016/j.eclinm.2023.101974.
|
| [19] |
Porte A, Barcelon JM, Budker RL, et al. Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulate[J]. Gynecol Oncol Rep, 2021, 36: 100782. DOI: 10.1016/j.gore.2021.100782.
|
| [20] |
Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia[J]. Lancet, 2017, 390(10110): 2343-2345. DOI: 10.1016/S0140-6736(17)32894-5.
|
| [21] |
Bolze PA, Patrier S, Massardier J, et al. PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes[J]. Int J Gynecol Cancer, 2017, 27(3): 554-561. DOI: 10.1097/IGC.0000000000000892.
|
| [22] |
Pisani D, Calleja-Agius J, Di Fiore R, et al. Epithelioid trophoblastic tumour: a case with genetic linkage to a child born over seventeen years prior, successfully treated with surgery and pembrolizumab[J]. Curr Oncol, 2021, 28(6): 5346-5355. DOI: 10.3390/curroncol28060446.
|
| [23] |
Winship AL, Alesi LR, Sant S, et al. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice[J]. Nat Cancer, 2022, 3(1): 1113. DOI: 10.1038/s43018-022-00413-x.
|
| [24] |
Garutti M, Lambertini M, Puglisi F. Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review[J]. ESMO Open, 2021, 6: 100276. DOI: 10.1016/j.esmoop.2021.100276.
|
| [25] |
Özdemir BC. Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology[J]. J ImmunoTherapy Cancer, 2021, 9: e002220. DOI: 10.1136/jitc-2020-002220.
|
| [26] |
Chen Z, Huang J, Kwak-Kim J, et al. Immune checkpoint inhibitors and reproductive failures[J]. J Reprod Immunol, 2023, 156: 103799. DOI: 10.1016/j.jri.2023.103799.
|
| [27] |
Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity[J]. Nat Rev Clin Oncol, 2022, 19(4): 254-267. DOI: 10.1038/s41571-022-00600-w.
|
| [28] |
Borgers JSW, Heimovaara JH, Cardonick E, et al. Immunotherapy for cancer treatment during pregnancy[J]. Lancet Oncol, 2021, 22(12): e550-e561. DOI: 10.1016/S1470-2045(21)00525-8.
|
| [29] |
Mehta A, Kim KB, Minor DR. Case report of a pregnancy during ipilimumab therapy[J]. J Glob Oncol, 2018, 4: 1-3. DOI: 10.1200/JGO.17.00019.
|
| [30] |
Menzer C, Beedgen B, Rom J, et al. Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy[J]. Eur J Cancer, 2018， 104：239-242. DOI： 10.1016/j.ejca.2018.09.008.
|
| [31] |
Xu W, Moor RJ, Walpole ET, et al. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature[J]. Melanoma Res, 2019, 29(3): 333-337. DOI: 10.1097/CMR.0000000000000586.
|
| [32] |
Bucheit AD, Hardy JT, Szender JB, et al. Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition[J]. Melanoma Res, 2020, 30(4): 423-425. DOI: 10.1097/CMR.0000000000000657.
|
| [33] |
Burotto M, Gormaz JG, Samtani S, et al. Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy[J]. Semin Oncol, 2018, 45(3): 164-169. DOI: 10.1053/j.seminoncol.2018.03.003.
|
| [34] |
Polnaszek B, Mullen M, Bligard K, et al. Term pregnancy after complete response of placental site trophoblastic tumor to immunotherapy[J]. Obstet Gynecol, 2021, 138(1): 115-118. DOI: 10.1097/AOG.0000000000004434.
|
| [35] |
Harrold EC, Ogle M, O′Brien E, et al. Fertility outcomes post immune checkpoint inhibitor exposure[J]. Cancer Cell, 2024, 42(11): 1808-1810. DOI: 10.1016/j.ccell.2024.10.005.
|